The first experience of using alteplase in the treatment of venous thromboembolic complications in women while taking oral contraceptives

Abstract

Introduction. Pulmonary embolism (PE) is potentially life-threatening complication that could develop in hormonal contraceptive users. Therapeutic thrombolysis is safe, relatively modern and effective method of treatment.

Aim of the study — to summarize our own experience of thrombolytic therapy of PE in women OC users.

We presented three cases of PE developed in association with oral contraceptive use. Tree female patients aged 20 years, 34 years, 47 years at admittance to hospital were diagnosed PE.

Result. All patients got thrombolytic therapy with alteplase 100 mg iv (10 mg bolus iv, then 90 mg continuous iv injection by infusomat). Good clinical outcomes were reached in all cases.

Conclusion. Our experience shows that alteplase is highly effective agent in PE treatment in women with TE after hormonal contraception.

Keywords: hormonal contraception; venous thrombosis; pulmonary embolism; thrombolysis.

Keywords

hormonal contraception / venous thrombosis / pulmonary embolism / thrombolysis

References

[1] Martinez F, Ramirez I, Perez-Campos E, Latorre K, Lete I. Venous and pulmonary thromboembolism and combined hormonal contraceptives. Systematic review and meta-analysis. Eur J Contracept Reprod Health Care. 2012;17(1):7–29.

[2] Martinez F., Ramirez I., Perez-Campos E., Latorre K., Lete I. Venous and pulmonary thromboembolism and combined hormonal contraceptives. Systematic review and meta-analysis // Eur J Contracept Reprod Health Care. 2012. Vol. 17. N 1. P. 7–29.

[3] De Bastos M, Stegeman BH, Rosendaal FR, Van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev. 2014;(3):CD010813.

[4] De Bastos M., Stegeman B.H., Rosendaal F.R., Van Hylckama Vlieg A., Helmerhorst F.M., Stijnen T., et al. Combined oral contraceptives: venous thrombosis // Cochrane Database Syst Rev. 2014. N 3. P. CD010813.

[5] Dinger JC, Heinemann LA, Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142 475 women-years of observation. Contraception. 2007;75(5): 344–354.

[6] Dinger J.C., Heinemann L.A., Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142 475 women-years of observation // Contraception. 2007. Vol. 75. N 5. P. 344–354.

[7] Bitzer J, Ahrendt HJ, Merkle E. Klinisch relevante pharmakologische Grundlagen der hormonellen Kontrazeption. Frauenarzt. 2009;50:348–354.

[8] Bitzer J., Ahrendt H.J., Merkle E. Klinisch relevante pharmakologische Grundlagen der hormonellen Kontrazeption // Frauenarzt. 2009. Vol. 50. P. 348–354.

[9] Bode H. Die Perspektive der 14-bis 25 2015. Available from: https://www.forschung.sexualaufklaerung.de/forschungsthemen/jugendsexualitaet/ projekt/jugend sexualitaet-2015-repraesentative-wiederholungsbefragungdie-perspektive-der-14-bis-25-jaehrige/.

[10] Bode H. Die Perspektive der 14-bis 25 2015. Available from: https://www.forschung.sexualaufklaerung.de/forschungsthemen/jugendsexualitaet/projekt/jugendsexualitaet-2015-repraesentative-wiederholungsbefragungdie-perspektive-der-14-bis-25-jaehrige/.

[11] Schubert I et al. Verordnungen hormonaler Kontrazeptiva an junge Frauen; Studie im Auftrag des BfArM vorgelegt im Februar 2017 von der PMV Forschungsgruppe an der Universität Köln, dem wissenschaftlichen Institut der AOK (WIdO) Berlin und der Karls-Universität Prag. Februar 2017. Available from: http:// www.bfarm.de/ SharedDocs/Downloads/DE/Arzneimittel/Pharmakovigilanz/Bulletin/2017/2-2017.pdf? blob= publicationFile&v=6.

[12] Schubert I. et al. Verordnungen hormonaler Kontrazeptiva an junge Frauen; Studie im Auftrag des BfArM vorgelegt im Februar 2017 von der PMV Forschungsgruppe an der Universität Köln, dem wissenschaftlichen Institut der AOK (WIdO) Berlin und der Karls-Universität Prag. Februar 2017. Available from: http://www.bfarm.de/SharedDocs/Downloads/DE/Arzneimittel/Pharmakovigilanz/Bulletin/2017/2-2017.pdf? blob= publicationFile&v=6.

[13] Blickpunkt I. Thromboembolie: Kontrazeptiva der 3. und 4. Generation seltener verordnet… in Frankreich, leider nicht in Deutschland. Arznei-Telegramm. 2015:46:41–42. https://www.arznei-telegramm.de/html/sonder/1505041_02.html

[14] Blickpunkt I. Thromboembolie: Kontrazeptiva der 3. und 4. Generation seltener verordnet in Frankreich, leider nicht in Deutschland // Arznei-Telegramm. 2015. B. 46. S. 41–42. https://www.arznei-telegramm.de/html/sonder/1505041_02.html

[15] Etude de l’impact de la modification récente des méthodes de contraception sur la survenue d’embolies pulmonaires chez les femmes de 15 à 49 ans. Point d’Information. ANSM. 2014. Available from: http://www.a-turl.de/?k=oswi

[16] Etude de l’impact de la modification récente des méthodes de contraception sur la survenue d’embolies pulmonaires chez les femmes de 15 à 49 ans. Point d’Information // ANSM. 2014. Available from: http://www.a-turl.de/?k=oswi

[17] Lidegaard O, Nielsen LH, Skovlund CW, Skjeldestad FE, Lokkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ. 2011;343:d6423.

[18] Lidegaard O., Nielsen L.H., Skovlund C.W., Skjeldestad F.E., Lokkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9 // BMJ. 2011. Vol. 343. P. d6423.

[19] Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ. 2001;323(7305):131–134.

[20] Kemmeren J.M., Algra A., Grobbee D.E. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis // BMJ. 2001. Vol. 323. N 7305. P. 131–134.

[21] Stocco B, Fumagalli HF, Franceschini SA, Martinez EZ, Marzocchi-Machado CM, de Sa MF, et al. Comparative study of the effects of combined oral contraceptives in hemostatic variables: an observational preliminary study. Medicine (Baltimore). 2015;94(4):e385.

[22] Stocco B., Fumagalli H.F., Franceschini S.A., Martinez E.Z., Marzocchi-Machado C.M., de Sa M.F., et al. Comparative study of the effects of combined oral contraceptives in hemostatic variables: an observational preliminary study // Medicine (Baltimore). 2015. Vol. 94. N 4. P. e385.

[23] Van Vliet HA, Bertina RM, Dahm AE, Rosendaal FR, Rosing J, Sandset PM, et al. Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor. J Thromb Haemost. 2008;6(2):346–351.

[24] Van Vliet H.A., Bertina R.M., Dahm A.E., Rosendaal F.R., Rosing J., Sandset P.M., et al. Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor // J Thromb Haemost. 2008. Vol. 6. N 2. P. 346–351.

[25] Fan X, Chen X, Wang C, Dai J, Lu Y, Wang K, et al. Drospirenone enhances GPIb-IX-V-mediated platelet activation. J Thromb Haemost. 2015;13(10):1918–1924.

[26] Fan X., Chen X., Wang C., Dai J., Lu Y., Wang K., et al. Drospirenone enhances GPIb-IX-V-mediated platelet activation // J Thromb Haemost. 2015. Vol. 13. N 10. P. 1918–1924.

[27] Ziller M, Ziller V, Haas G, Rex J, Kostev K. Risk of venous thrombosis in users of hormonal contraceptives in German gynaecological practices: a patient database analysis. Arch Gynecol Obstet. 2014;289(2):413–419.

[28] Ziller M., Ziller V., Haas G., Rex J., Kostev K. Risk of venous thrombosis in users of hormonal contraceptives in German gynaecological practices: a patient database analysis // Arch Gynecol Obstet. 2014. Vol. 289. N 2. P. 413–419.

[29] Klipping C, Duijkers I, Parke S, Mellinger U, Serrani M, Junge W. Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel. Drugs in R&D. 2011;11(2):159–170.

[30] Klipping C., Duijkers I., Parke S., Mellinger U., Serrani M., Junge W. Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel // Drugs in R&D. 2011. Vol. 11. N 2. P. 159–170.

[31] Gaussem P, Alhenc-Gelas M, Thomas JL, Bachelot-Loza C, Remones V, Ali FD, et al. Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17beta-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A doubleblind, randomised study. Thromb Haemost. 2011;105(3):560–567.

[32] Gaussem P., Alhenc-Gelas M., Thomas J.L., Bachelot-Loza C., Remones V., Ali F.D., et al. Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17beta-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A doubleblind, randomised study // Thromb Haemost. 2011. Vol. 105. N 3. P. 560–567.

[33] Foth D, Römer T, Ahrendt H-J. Hormonelle Kontrazeption mit östradiolhaltigen Kombinationspräparaten. Gynäkologische Endokrinologie. 2013;11(3):162–167.

[34] Foth D., Römer T., Ahrendt H.-J. Hormonelle Kontrazeption mit östradiolhaltigen Kombinationspräparaten // Gynäkologische Endokrinologie. 2013. Bd. 11. N 3. S. 162–167.

[35] Lidegaard O, Nielsen LH, Skovlund CW, Lokkegaard E. Venous thrombosis in users of non-oral hormonal contraception: follow- up study, Denmark 2001–10. BMJ. 2012;344:e2990.

[36] Lidegaard O., Nielsen L.H., Skovlund C.W., Lokkegaard E. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001–10 // BMJ. 2012. Vol. 344. P. e2990.

[37] Dore DD, Norman H, Loughlin J, Seeger JD. Extended case-control study results on thromboembolic outcomes among trans dermal contraceptive users. Contraception. 2010;81(5):408–413.

[38] Dore D.D., Norman H., Loughlin J., Seeger J.D. Extended case-control study results on thromboembolic outcomes among trans dermal contraceptive users // Contraception. 2010. Vol. 81. N 5. P. 408–413.

[39] WHO. Medical Eligibility Criteria for Contraceptive Use, 5th edition. World Health Organization; 2015. Available from: http://apps.who.int/iris/bitstream/handle/10665/181468/9789241549158_eng.pdf; jsessionid=C382414CD818D52A35 F64DFC7A3A95FC?sequence=1

[40] WHO. Medical Eligibility Criteria for Contraceptive Use. 5th edition. World Health Organization, 2015. Available from: http://apps.who.int/iris/bitstream/handle/10665/181468/9789241549158_eng.pdf; jsessionid=C382414CD818D52A35F64DFC7A3A95FC?sequence=1

[41] (MMWR) MaMWR. U. S. Medical Eligibility Criteria for Contraceptive Use, 2010. Available from: https://www.cdc.gov/ mmwr/pdf/rr/rr59e0528.pdf

[42] (MMWR) MaMWR. U. S. Medical Eligibility Criteria for Contraceptive Use, 2010. Available from: https://www.cdc.gov/mmwr/pdf/rr/rr59e0528.pdf

[43] Healthcare FFSR, FSRH. UK Medical Eligibility Criteria for Contraceptive Use 2016. CreateSpace Independent Publishing Platform; 2016.

[44] Healthcare FFSR, FSRH. UK Medical Eligibility Criteria for Contraceptive Use 2016. Create Space Independent Publishing Platform, 2016.

[45] Tepper NK, Whiteman MK, Marchbanks PA, James AH, Curtis KM. Progestin-only contraception and thromboembolism: A systematic review. Contraception. 2016;94(6):678–700.

[46] Tepper N.K., Whiteman M.K., Marchbanks P.A., James A.H., Curtis K.M. Progestin-only contraception and thromboembolism: A systematic review // Contraception. 2016. Vol. 94. N 6. P. 678–700.

[47] Van Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR. The risk of deep venous thrombosis associated with injectable epotmedroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol. 2010;30(11):2297–2300.

[48] Van Hylckama Vlieg A., Helmerhorst F.M., Rosendaal F.R. The risk of deep venous thrombosis associated with injectable epotmedroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device // Arterioscler Thromb Vasc Biol. 2010. Vol. 30. N 11. P. 2297–2300.

[49] Beyer-Westendorf J, Bauersachs R, Hach-Wunderle V, Zotz RB, Rott H. Sex hormones and venous thromboembolism — from contraception to hormone replacement therapy. Vasa. 2018;47(6):441–450.

[50] Beyer-Westendorf J., Bauersachs R., Hach-Wunderle V., Zotz R.B., Rott H. Sex hormones and venous thromboembolism — from contraception to hormone replacement therapy // Vasa. 2018. Vol. 47. N 6. P. 441–450.

[51] Prud VA. Changes in the parameters of the hemostasis system in patients using hormonal contraceptives. Dal’nevostochnyy meditsinskiy zhurnal. 2016;(4):27–30. (In Russ).

[52] Пруд В.А. Изменение показателей системы гемостаза у пациенток, применяющих гормональные контрацептивы // Дальневосточный мед. журн. 2016. № 4. С. 27–30.

[53] Stegeman BH, de Bastos M, Rosendaal FR, A van Hylckama Vlieg, Helmerhorst FM, Stijnen T, Dekkers OM. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. BMJ. 2013;347:f5298. doi: 10.1136/bmj.f5298

[54] Stegeman B.H., de Bastos M., Rosendaal F.R., A van Hylckama Vlieg, Helmerhorst F.M., Stijnen T., Dekkers O.M. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis // BMJ. 2013. Vol. 347. P. f5298. doi:10.1136/bmj.f5298

[55] Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015;12(8):464–474. doi: 10.1038/nrcardio.2015.83

[56] Heit J.A. Epidemiology of venous thromboembolism // Nat Rev Cardiol. 2015. Vol. 12. N 8. P. 464–474. doi:10.1038/nrcardio.2015.83

[57] Savel’yev VS. Thromboembolism of the pulmonary arteries. In: Savel’yev VS, ed. Flebologiya. Rukovodstvo dlya vrachey. Moscow: Meditsina; 2001:279–319. (In Russ).

[58] Савельев B.C. Тромбоэмболия легочных артерий // Савельев B.C., ред. Флебология. Руководство для врачей. М.: Медицина, 2001. с. 279–319.

[59] Bokeriya LA, Zatevakhin II, Kiriyenko AI, Andriyashkin AV, Andriyashkin VV, Arutyunov GP, et al. Russian Clinical Guidelines for the Diagnosis, Treatment and Prevention of Venous Thromboembolic Complications. Flebologiya. 2015;9(4–2). (In Russ).

[60] Бокерия Л.А., Затевахин И.И., Кириенко А.И., Андрияшкин А.В., Андрияшкин В.В., Арутюнов Г.П., и др. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений // Флебология. 2015. Т. 9. № 4-2.

[61] Reed M, Kerndt CC, Nicolas D. Alteplase. StatPearls Publishing; 2020.

[62] Reed M., Kerndt C.C., Nicolas D. Alteplase. StatPearls Publishing, 2020.

[63] Jala S, O’Brien E. Treatment with intravenous alteplase for acute ischemic stroke after reversal of dabigatran with idarucizumab: a case study. J Neurosci Nurs. 2019;51(1):21–25.

[64] Jala S., O’Brien E. Treatment with intravenous alteplase for acute ischemic stroke after reversal of dabigatran with idarucizumab: a case study // J Neurosci Nurs. 2019. Vol. 51. N 1. P. 21–25.

[65] Mosimah CI, Murray PJ, Simpkins JW. Not all clots are created equal: a review of deficient thrombolysis with tissue plasminogen activator (tPA) in patients with metabolic syndrome. Int J Neurosci. 2019;129(6):612–618.

[66] Mosimah C.I., Murray P.J., Simpkins J.W. Not all clots are created equal: a review of deficient thrombolysis with tissue plasminogen activator (tPA) in patients with metabolic syndrome // Int J Neurosci. 2019. Vol. 129. N 6. P. 612–618.

[67] Ovchinnikov YuV, Linchak RM, Zelenov MV. Comparative characteristics of alteplase and prourokinase during thrombolysis of massive pulmonary embolism. Vestnik Rossiyskoy voyenno-meditsinskoy akademii. 2015;4(52):124–128. (In Russ).

[68] Овчинников Ю.В., Линчак Р.М., Зеленов М.В. Сравнительная характеристика альтеплазы и проурокиназы при проведении тромболизиса массивной тромбоэмболии легочной артерии // Вестник Российской военно-медицинской академии. 2015. Т. 4. № 52. С. 124–128.

[69] Agnelli G, Becattini C, Kirschstein T. Thrombolysis vs heparin in the treatment of pulmonary embolism: a clinical outcome-based metaanalysis. Arch Int Med. 2002;162:2537–2541.

[70] Agnelli G., Becattini C., Kirschstein T. Thrombolysis vs heparin in the treatment of pulmonary embolism: a clinical outcome-based metaanalysis // Arch Int Med. 2002. Vol. 162. P. 2537–2541.

[71] Stein P, Matta F, Steinberger D, Keyes D. Intracerebral hemorrhage with thrombolytic therapy for acute pulmonary embolism. Am J Med. 2012;125(Is.1).

[72] Stein P., Matta F., Steinberger D., Keyes D. Intracerebral hemorrhage with thrombolytic therapy for acute pulmonary embolism // Am J Med. 2012. Vol. 125. Is.1.

[73] Kiriyenko AI, Leont’yev SG, Karalkin AV, Mironov AV, Bardina EA, Babakova NA, Ustinov FS. Possibilities of thrombolytic therapy for massive pulmonary embolism: urokinase and alteplase. Flebologiya. 2013;7(3):27–33. (In Russ).

[74] Кириенко А.И., Леонтьев С.Г., Каралкин А.В., Миронов А.В., Бардина Е.А., Бабакова Н.А, Устинов Ф.С. Возможности тромболитической терапии массивной эмболии легочных артерий: урокиназа и альтеплаза // Флебология. 2013. Т. 7. № 3. С. 27–33.

[75] Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thrombol Haemost. 2007;98(4):756–764.

[76] Cohen A.T., Agnelli G., Anderson F.A., Arcelus J.I., Bergqvist D., Brecht J.G., et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality // Thrombol. Haemost. 2007. Vol. 98. N 4. P. 756–764.

[77] Bonderman D, Wilkens H, Wakounig S, Schäfers H-J, Jansa P, Lindner J, et al. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J. 2009;33(2):325–331.

[78] Bonderman D., Wilkens H., Wakounig S., Schäfers H.-J., Jansa P., Lindner J., et al. Risk factors for chronic thromboembolic pulmonary hypertension // Eur Respir J. 2009. Vol. 33. N 2. P. 325–331.

[79] Condliffe R, Kiely DG, Gibbs JSR, Corris PA, Peacock AJ, Jenkins DP, et al. Prognostic and aetiological factors in chronic thrombo-embolic pulmonary hypertension. Eur Respir J. 2009;33(2):332–338.

[80] Condliffe R., Kiely D.G., Gibbs J.S.R., Corris P.A., Peacock A.J., Jenkins D.P., et al. Prognostic and aetiological factors in chronic thrombo-embolic pulmonary hypertension // Eur Respir J. 2009. Vol. 33. N 2. P. 332–338.

[81] Fanikos J, Piazza G, Zayaruzny M, Goldhaber SZ. Long-term complications of medical patients with hospital-acquired venous thromboembolism. Thromb Haemost. 2009;102(4):688–693.

[82] Fanikos J., Piazza G., Zayaruzny M., Goldhaber S.Z. Long-term complications of medical patients with hospital-acquired venous thromboembolism // Thromb Haemost. 2009. Vol. 102. N 4. P. 688–693.

[83] Aujesky D, Jiménez D, Mor MK, Geng M, Fine MJ, Ibrahim SA. Weekend versus weekday admission and mortality after acute pulmonary embolism. Circulation. 2009;119:7:962–968.

[84] Aujesky D., Jiménez D., Mor M.K., Geng M., Fine M.J., Ibrahim S.A. Weekend versus weekday admission and mortality after acute pulmonary embolism // Circulation. 2009. Vol. 119. N 7. P. 962–968.

[85] Aymard T, Kadner A, Widmer A, Basciani R, Tevaearai H, Weber A, et al. Massive pulmonary embolism: surgical embolectomy versus thrombolytic therapy — should surgical indications be revisited? Eur J Cardiothorac Surg. 2013;43(1):90–94.

[86] Aymard T., Kadner A., Widmer A., Basciani R., Tevaearai H., Weber A., et al. Massive pulmonary embolism: surgical embolectomy versus thrombolytic therapy — should surgical indications be revisited? // Eur J Cardiothorac Surg. 2013. Vol. 43. N 1. P. 90–94.

[87] Lehnert P, Møller CH, Carlsen J, Grande P, Steinbrüchel DA. Surgical treatment of acute pulmonary embolism — a 12-year retrospective analysis. Scand Cardiovasc J. 2012;46(3):172–176.

[88] Lehnert P., Møller C.H., Carlsen J., Grande P., Steinbrüchel D.A. Surgical treatment of acute pulmonary embolism — a 12-year retrospective analysis // Scand Cardiovasc J. 2012. Vol. 46. N 3. P. 172–176.

[89] Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ. Antithrombotic Therapy Prevention of Thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl.):7S–47S. doi: 10.1378/chest.1412S3

[90] Guyatt G.H., Akl E.A., Crowther M., Gutterman D.D., Schuünemann H.J. Antithrombotic Therapy Prevention of Thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines // Chest. 2012. Vol. 141. N 2. Suppl. P. 7S–47S. doi: 10.1378/chest.1412S3

[91] Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS study: a randomized controlled trial. JAMA. 1999;282:2019–2026.

[92] Clark W.M., Wissman S., Albers G.W., Jhamandas J.H., Madden K.P., Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS study: a randomized controlled trial // JAMA. 1999. Vol. 282. P. 2019–2026.

[93] Kanter DS, Mikkola KM. Thrombolytic therapy for pulmonary embolism: frequency of intracranial hemorrhage and associated risk factors. Chest. 1997;111:1241–1245.

[94] Kanter D.S., Mikkola K.M. Thrombolytic therapy for pulmonary embolism: frequency of intracranial hemorrhage and associated risk factors // Chest. 1997. Vol. 111. P. 1241–1245.

[95] Gürbüz ÖZ, Öner FA, Akyay AI, Coşkun Yu, Mecdi E. The results of streptokinase therapy in acute pulmonary embolism with intermediate and high risk. Turk Thorac J. 2012;13:6–10.

[96] Gürbüz Ö.Z., Öner F.A., Akyay A.I., Coşkun Yu., Mecdi E. The results of streptokinase therapy in acute pulmonary embolism with intermediate and high risk // Turk Thorac J. 2012. Vol. 13. P. 6–10.

[97] The UKEP study Research Group. The UKEP study: Multicentre clinical trial on two local regimens of urokinase in massive pulmonary embolism. Eur Heart J. 1987;8(1):2–10.

[98] The UKEP study: Multicentre clinical trial on two local regimens of urokinase in massive pulmonary embolism // Eur Heart J. 1987. Vol. 8. N 1. P. 2–10.

[99] Marini C, Di Ricco G, Rossi G, Rindi M, Palla R, Giuntini C. Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism a randomized clinical trial. Respiration. 1988;54:162–173.

[100] Marini C., Di Ricco G., Rossi G., Rindi M., Palla R., Giuntini C. Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism a randomized clinical trial // Respiration. 1988. Vol. 54. P. 162–173.

[101] Tibbutt DA, Davies JA, Anderson JA, Fletcher EW, Hamill J, Holt JM, et al. Comparison by controlled clinical trial of streptokinase and heparin in treatment of life-threatening pulmonary embolism. Br Med J. 1974:1:343–347.

[102] Tibbutt D.A., Davies J.A., Anderson J.A., Fletcher E.W., Hamill J., Holt J.M., et al. Comparison by controlled clinical trial of streptokinase and heparin in treatment of life-threatening pulmonary embolism // Br Med J. 1974. Vol. 1. P. 343–347.

[103] De Gregorio MÁ, Laborda A, de Blas I, Medrano J, Mainar A, Oribe M. Endovascular Treatment of a Haemodynamically Unstable Massive Pulmonary Embolism using Fibrinolysis and Fragmentation. Experience with 111 Patients in a Single Centre. Why don’t we follow ACCP Recommendations? Arch Bronconeumol. 2011;47(1):17–24.

[104] De Gregorio M.Á., Laborda A., de Blas I., Medrano J., Mainar A., Oribe M. Endovascular Treatment of a Haemodynamically Unstable Massive Pulmonary Embolism using Fibrinolysis and Fragmentation. Experience with 111 Patients in a Single Centre. Why don’t we follow ACCP Recommendations? // Arch Bronconeumol. 2011. Vol. 47. N 1. P. 17–24.

[105] Zhang Y, Sun T, He B, Wang L. Thrombolytic therapy with urokinase for pulmonary embolism in patients with stable hemodynamics. Med Sci Monit. 2007;13:1:CR20–23.

[106] Zhang Y., Sun T., He B., Wang L. Thrombolytic therapy with urokinase for pulmonary embolism in patients with stable hemodynamics // Med Sci Monit. 2007. Vol. 13. N 1. P. CR20–23.

RIGHTS & PERMISSIONS

Eco-Vector